

Press release



Medicon Valley Scandinavia, January 22, 2008

Vivolution acquires extensive patent portfolio from Bristol-Meyers Squibb

Vivolution has during the past 7 years operated under a world wide exclusive license for the technology used in the Vivostat® System but has now acquired all patents from Bristol-Meyers Squibb

ConvaTec, a subsidiary of Bristol-Meyer Squibb, who developed the Vivostat® System, and subsequently sold the project to Vivolution, has agreed to sell all patents covering the Vivostat technology and other related technologies for an undisclosed sum.

The patent portfolio covers 66 issued and 20 pending patents covering a large number of countries. The acquisition by Vivolution marks the end of a long relationship with ConvaTec and provides Vivolution with the option to out-license the technology to strategic partners.

"I am very happy that we have finalized the acquisition after three years of negotiation", says Tom Bjerg Lauritzen, CEO of Vivolution A/S. "We are now completely independent and can now develop our own patent strategy."

Vivolution is in the process of launching their second-generation product for the treatment of chronic ulcers. Chronic ulcers are a serious problem for many diabetic patients and there is currently no treatment available for this condition.

About VIVOLUTION

Vivolution is a privately owned company based in the Medicon Valley of Scandinavia. Our product, the Vivostat® System, utilizes the individual patient's blood to derive either a surgical sealant to prevent and stop bleedings, or a gel with a high concentration of growth factors (PRF®) that stimulates the healing of chronic wounds.

By using the patient's own blood there is no risk of allergic reactions or transfer of viral diseases. This is an increasingly important factor as more and new viruses, such as Asian bird flu etc. develop.

Our Products are sold via our own direct sales force and distributors throughout Europe and Asia - mainly to surgical departments and wound centres. More than 98% of our sale is export.

Press release



For further information please contact:

CEO Tom Bjerg Lauritzen
Tel. +45 8880 8420
E-Mail: tbl@vivolution.com

For information please visit: www.vivolution.com and www.vivostat.com